News All of Ferrer’s information, just a click away Home News normal Apply The World Health Organization includes the cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines . Tue, 08/01/2023 - 10:58 We allocate, on average, more than 40% of our profits to social and environmental projects for the third consecutive year . Wed, 07/26/2023 - 10:13 Ferrer4Future launches its open innovation challenge to drive digital solutions for ALS . Fri, 06/23/2023 - 07:24 We extend our clinical study in amyotrophic lateral sclerosis (ALS) . Thu, 06/22/2023 - 06:30 We’ve been awarded EcoVadis GOLD Rating! . Thu, 03/30/2023 - 09:29 Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP) . Wed, 02/22/2023 - 09:30 We achieve Great Place To Work certification in 5 countries . Tue, 11/29/2022 - 18:17 More than 500 people from Ferrer participate in positive impact activities in nine countries on the Days for Good . Fri, 10/07/2022 - 10:02 The polypill reduces cardiovascular mortality by 33% in patients treated after myocardial infarction . Thu, 08/25/2022 - 11:55 We invested more than 60% of our net profits in social and environmental causes . Thu, 07/28/2022 - 13:56 Cargar más For requests for interviews or information, please contact the Communications Department CONTACT US alternatively, please dial +34 936 003 779 See more R&D Strategy Business Development
The World Health Organization includes the cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines . Tue, 08/01/2023 - 10:58
We allocate, on average, more than 40% of our profits to social and environmental projects for the third consecutive year . Wed, 07/26/2023 - 10:13
Ferrer4Future launches its open innovation challenge to drive digital solutions for ALS . Fri, 06/23/2023 - 07:24
Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP) . Wed, 02/22/2023 - 09:30
More than 500 people from Ferrer participate in positive impact activities in nine countries on the Days for Good . Fri, 10/07/2022 - 10:02
The polypill reduces cardiovascular mortality by 33% in patients treated after myocardial infarction . Thu, 08/25/2022 - 11:55
We invested more than 60% of our net profits in social and environmental causes . Thu, 07/28/2022 - 13:56